Get Involved Become a Donor
Updated: 2011-12-22 01:48:14
Home Events Symposium Other Events Past Events Gala 2012 Free Symposium Sponsorship and Ticketing About Us What We Do and Why How We Came to Be Partnership with IMHRO Luminary Awards Resources Local Help Facts Figures Warning Signs Depression Schizophrenia Bipolar Disorder Glossary of Terms Useful Links Get Involved Sunshine Volunteers Become a Donor Sponsorship and Ticketing Sunshine Shopping News and Videos Contact Get Involved Become a Donor This e-mail address is being protected from spambots . You need JavaScript enabled to view it . Enter your Name E-mail address Message Subject Address : Phone Amount to donate : I would like my donation to be made in the memory of : I would like my donation to be made in honor of : Please send an acknowledgement : to Enter your Message E-mail a copy
WASHINGTON -- An FDA advisory panel punted on the question of approval for an inhaled version of the antipsychotic drug loxapine (Adasuve) to treat agitation in bipolar and schizophrenic patients, despite the risk for respiratory side effects.